Antibodies to stimulate host immunity: Lessons from ipilimumab Book Section
| Authors: | Callahan, M. K.; Postow, M. A.; Wolchok, J. D. |
| Editors: | Prendergast, G. C.; Jaffee, E. M. |
| Article/Chapter Title: | Antibodies to stimulate host immunity: Lessons from ipilimumab |
| Abstract: | Ipilimumab is the first drug to show a survival benefit for patients with advanced melanoma and was approved by the US Food and Drug Administration in March of 2011. Ipilimumab enhances antitumor immunity by enhancing T-cell function by blocking the negative regulatory molecule, cytotoxic T-lymphocyte antigen 4 (CTLA-4). Unlike traditional cancer therapy, ipilimumab's effects may be delayed and occur after initial apparent disease progression. A distinct set of side effects have been described, and ongoing efforts continue to characterize immunologic changes associated with patients who benefit from therapy. Efforts to characterize ipilimumab's clinical activity in malignancies other than melanoma are ongoing. © 2013 Elsevier Inc. All rights reserved. |
| Keywords: | ipilimumab; melanoma; immunotherapy; ctla-4; cytotoxic t-lymphocyte antigen 4; checkpoint blockade; yervoy |
| Book Title: | Cancer Immunotherapy: Immune Suppression and Tumor Growth. 2nd ed |
| ISBN: | 978-0-12-394296-8 |
| Publisher: | Elsevier Inc. |
| Publication Place: | Amsterdam, Netherlands |
| Date Published: | 2007-01-01 |
| Start Page: | 287 |
| End Page: | 307 |
| Language: | English |
| DOI: | 10.1016/b978-0-12-394296-8.00019-1 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book chapter 19 -- Cancer Immunother.: Immune Suppr. and Tumor Growth: Second Ed. -- 9780123942968 (ISBN) -- Export Date: 8 July 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work